Results 181 to 190 of about 11,219 (248)

Reply to Schier [PDF]

, 2017
Haecker, Frank-Martin, Mayr, Johannes
core  

Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience. [PDF]

J Neurol
Rossini E, Di Stefano V, Iorio R, Habetswallner F, Maestri M, Vinciguerra C, Pennisi EM, Di Martino G, Rini N, Falso S, Marini S, Ricciardi D, Guida M, Morino S, Garibaldi M, Leonardi L, Marando D, Tufano L, Antonini G, Fionda L.   +19 more
europepmc   +1 more source

An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts [PDF]

core   +1 more source

Efgartigimod non-responders after the first treatment cycle in generalized myasthenia gravis: a retrospective analysis of predictive factors. [PDF]

Front Neurol
Niu Z, Wang J, Ren J, Liu R, Guo J, Zhang N, Zheng Y, Hao H, Gao F, Jin H.   +9 more
europepmc   +1 more source

Complement inhibitor therapy as a steroid-sparing strategy in generalized myasthenia gravis. [PDF]

Ther Adv Neurol Disord
Marini S, Falso S, Habetswallner F, Marini M, Iorio R.   +4 more
europepmc   +1 more source

The Use of Parabulbar and Sub-Tenon Injections to Correct Isolated Resistant Diplopia in Patients With Generalized Myasthenia Gravis: A Long Road to Clinically Meaningful Success. [PDF]

Clin Case Rep
Marchuk M, Sanin V, Mamilov V, Zinchenko M.   +3 more
europepmc   +1 more source

Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications. [PDF]

Biomedicines
Mansour GK, Alangari L, Khosyfan L, Alhammad R, Hajjar AW.   +4 more
europepmc   +1 more source

The efficacy, safety, and pharmacokinetics/pharmacodynamics of telitacicept following efgartigimod in generalized myasthenia gravis: protocol of a randomized controlled trial. [PDF]

Front Immunol
Li J, Zhang Y, Deng Y, Li W, Wang Y, Qi F, Zhang Q, Wan B, Li X, Weng Y, Fang Z, Zhang Y, Qu X, Pan S, Yang S, Zhang X.   +15 more
europepmc   +1 more source

Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach. [PDF]

Muscle Nerve
Hoffmann S, Zhao S, Callewaert F, Schoppe S, Rózsa C, Spillane J.   +5 more
europepmc   +1 more source